<DOC>
	<DOC>NCT01128894</DOC>
	<brief_summary>This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.</brief_summary>
	<brief_title>A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.</brief_title>
	<detailed_description>This randomized, open-label, multicenter, 2 parallel-group study evaluates the efficacy and safety of a weekly subcutaneously injected dose of albiglutide as compared with liraglutide. Subjects with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetics will be recruited into the study.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosis of type 2 diabetes mellitus and experiencing inadequate glycemic control on their current regimen of metformin, TZD, SU, or any combination of these oral antidiabetic medications BMI &gt;/=20kg/m2 and &lt;/=45 kg/m2 Fasting Cpeptide &gt;/=0.8 ng/mL (&gt;/=0.26 nmol/L) HbA1c between 7.0% and 10.0%, inclusive Female subjects of childbearing potential must be practicing adequate contraception. History of cancer History of treated diabetic gastroparesis Current biliary disease or history of pancreatitis History of significant GI surgery Recent clinically significant cardiovascular and/or cerebrovascular disease Hypertension History of human immunodeficiency virus infection History of or current liver disease or acute symptomatic infection with hepatitis B or hepatitis C History of alcohol or substance abuse Female subject is pregnant, lactating, or &lt;6 weeks postpartum Known allergy to any GLP 1 analogue, liraglutide, other study medications' excipients, excipients of albiglutide, or Baker's yeast History of type 1 diabetes mellitus Contraindications (as per the prescribing information) for the use of either background or potential randomized study medications (e.g., liraglutide) Receipt of any investigational drug or liraglutide within the 30 days or 5 half lives, whichever is longer, before Screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization or receipt of albiglutide in previous studies History or family history of thyroid disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK716155</keyword>
	<keyword>liraglutide</keyword>
	<keyword>albiglutide</keyword>
	<keyword>open-label</keyword>
</DOC>